Pharmaceuticals

QUAISR APPLICATION

Oral solid dosage (OSD) process selection

End-to-end integration of heterogeneous process models.

Challenge.
End-to-end OSD process modelling with multiple tools and teams is challenging.
Solution.
Use Quaisr to streamline process selection by connecting existing modelling & simulation initiatives, supporting engineering models, financial models, sustainability models from multiple teams in one place. Optimise tablet design by integrating unit-operation simulations, material properties models, and structural performance models.
Impact.
Accelerate time to market by creating and sharing internal digital applications to select manufacturing processes, meet manufacturability constraints and boost operational decision support.

QUAISR APPLICATION

Sustainability compliance for manufacturing

Operational excellence with end-to-end optimisation.

Challenge.
Process decisions involve complex tradeoffs between operating margins, energy and material consumption.
Solution.
Use Quaisr to identify optimal operating conditions that maximise product yield, while minimising energy and solvent consumption. Support robust decisions using in-built surrogate modelling and multi-objective optimisation strategies. All decisions and supporting data are tracked and versioned for regulatory audit.
Impact.
Decrease OPEX while responding to company wide strategice objectives like low carbon emissions and sustainability.

QUAISR APPLICATION

Patient recruitment for clinical trials

Real-time aggregation of complex data sources.

Challenge.
Extensive statistical analysis is required to achieve balanced clinical trial populations.
Solution.
Use Quaisr to inform patient recruitment and aggregate data from multiple research sites, identify trends and track anomalies. Workflows are used to inform protocol design, identify incomplete records, and track data diversity. Teams reduce siloed working conditions by sharing automated workflows among internal statisticians and external contractors.
Impact.
Faster clinical trials while conforming to regulatory body mandates.
30% - 40%
Faster design cycles
10% - 15%
Reduced OPEX
2x - 3x
Faster clinical trials